REG - AstraZeneca PLC - Director/PDMR Shareholding

AstraZenecaAnnouncement

15/02/2021 15:00

RNS Number : 1459P
  
AstraZeneca PLC
  
15 February 2021
  
 

15 February 2021 15:00 GMT
 
Transactions by Persons Discharging Managerial Responsibilities
 
AstraZeneca PLC (the Company) announced that, on 11 February 2021, awards of the Company's ordinary shares of $0.25 each (Ordinary Shares) vested to certain Persons Discharging Managerial Responsibilities of the Company (PDMRs) under the AstraZeneca Investment Plan (AZIP).
 
The AZIP awards were granted in 2013 and were subject to a four-year performance period followed by a four-year holding period before vesting. The majority of Mr Soriot's 2013 AZIP award was granted in order to compensate him for a loss of remuneration opportunity at his previous employer. Application of the performance measures specified at the time of grant resulted in 100% of the AZIP award vesting.
 
Following the reinvestment of dividends accrued during the performance and holding periods and the withholding of shares to satisfy certain tax obligations arising on vesting, the PDMRs' beneficial interests in Ordinary Shares changed as detailed in the table below:
 




PDMR


Ordinary Shares acquired under the AZIP




Pascal Soriot


107,715




Marc Dunoyer


6,289




 
 
For tax purposes, the fair market value of an Ordinary Share at vest was 7247 pence, being the closing price on the last trading day preceding the vesting.
 
Further details are set out in the attached notifications, made in accordance with the requirements of the EU and UK Market Abuse Regulations.
 
 




1 
 


Details of the person discharging managerial responsibilities / person closely associated 




a)
 


Name 


Pascal Soriot




2 
 


Reason for the notification 
 




a) 
 


Position/status 
 


Chief Executive Officer




b)
 


Initial notification /Amendment


Initial notification




3 
 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 




a) 
 


Name 


AstraZeneca PLC




b) 
 


LEI 


PY6ZZQWO2IZFZC3IOL08




4i
 


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted 




a) 
 


Description of the financial instrument, type of instrument 
 
Identification code 


Ordinary Shares of US$0.25 each in AstraZeneca PLC
 
 
GB0009895292
 




b) 
 


Nature of the transaction 
 
 


Acquisition of ordinary shares pursuant to a vesting under the AstraZeneca Investment Plan, for nil consideration.




c) 
 


Price(s) and volume(s) 
 


 




Price(s)


Volume(s)




0


107,715




 




d) 
 


Aggregated information 
 
- Aggregated volume 
- Price 


Not applicable - single transaction
 
 
 
 




e) 
 


Date of the transaction 
 


11 February 2021




f) 
 


Place of the transaction 
 


Outside a trading venue




 
 




1 
 


Details of the person discharging managerial responsibilities / person closely associated 




a)
 


Name 


Marc Dunoyer




2 
 


Reason for the notification 
 




a) 
 


Position/status 
 


Chief Financial Officer




b)
 


Initial notification /Amendment


Initial notification




3 
 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 




a) 
 


Name 


AstraZeneca PLC




b) 
 


LEI 


PY6ZZQWO2IZFZC3IOL08




4i 
 


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted 




a) 
 


Description of the financial instrument, type of instrument 
 
Identification code 


Ordinary Shares of US$0.25 each in AstraZeneca PLC
 
 
GB0009895292
 




b) 
 


Nature of the transaction 
 
 


Acquisition of ordinary shares pursuant to a vesting under the AstraZeneca Investment Plan, for nil consideration.




c) 
 


Price(s) and volume(s) 
 


 




Price(s)


Volume(s)




0


6,289




 




d) 
 


Aggregated information 
 
- Aggregated volume 
- Price 


Not applicable - single transaction
 
 
 
 




e) 
 


Date of the transaction 
 


11 February 2021




f) 
 


Place of the transaction 
 


Outside a trading venue




AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca. 
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
 
 
Adrian Kemp

Company Secretary
AstraZeneca PLC
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
DSHUVOORANUUAAR